This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Sk Chemicals Co., Ltd.. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Su-Jeen Lee: Innovator in Cell Line Development
Introduction
Su-Jeen Lee is a prominent inventor based in Gyeongg-do, South Korea. She has made significant contributions to the field of biotechnology, particularly in the development of cell lines for vaccine production. Her innovative work has the potential to enhance vaccine development processes.
Latest Patents
Su-Jeen Lee holds a patent for "MDCK-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells." This patent discloses a Madin-Darby canine kidney (MDCK)-derived cell line, which is prepared through serum-free culture and suspension culture methods. The MDCK-derived cell line is characterized by low or no tumorigenicity and includes specific cell lines such as MDCK Sky1023, MDCK Sky10234, and MDCK Sky3851. The patent also outlines a culture method for growing these cells and a method for producing a vaccine virus using them.
Career Highlights
Su-Jeen Lee is currently associated with SK Chemicals Co., Ltd., where she continues to advance her research and development efforts. Her work at the company focuses on innovative solutions in the biotechnology sector, particularly in vaccine production.
Conclusion
Su-Jeen Lee's contributions to the field of biotechnology, especially through her patented cell lines, demonstrate her commitment to advancing medical science. Her work has the potential to significantly impact vaccine development and public health.